SEC Comment Letter for Sorrento Therapeutics, Inc. (SRNE) (CIK 0000850261) — Sep 7, 2022
Sorrento Therapeutics, Inc. (SRNE) (CIK 0000850261)
Date: Sept. 7, 2022 · CIK: 0000850261 · Accession: 0000000000-22-009713
AI Filing Summary & Sentiment
File numbers found in text: 001-36150
Letter
United States securities and exchange commission logo September 7, 2022 Henry Ji Chairman of the Board, CEO and President Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, CA 92121 Re:Sorrento Therapeutics, Inc. Form 10-K for the year ended December 31, 2021 Filed March 11, 2022 Form 10-Q for the period ended March 31, 2022 Filed May 5, 2022 Form 10-Q for the period ended June 30, 2022 Filed August 15, 2022 File No. 001-36150 Dear Dr. Ji: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
September 7, 2022
Henry Ji
Chairman of the Board, CEO and President
Sorrento Therapeutics, Inc.
4955 Directors Place
San Diego, CA 92121
Re:Sorrento Therapeutics, Inc.
Form 10-K for the year ended December 31, 2021
Filed March 11, 2022
Form 10-Q for the period ended March 31, 2022
Filed May 5, 2022
Form 10-Q for the period ended June 30, 2022
Filed August 15, 2022
File No. 001-36150
Dear Dr. Ji:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences